APIs for research and impurities

N-Desmethyl trimeprazine is a synthetic compound, which is an impurity of the drug product. It is not active and does not possess any biological activity. It is a metabolite of the parent drug, Trimeprazine. N-Desmethyl trimeprazine has been studied for its pharmacological properties and metabolism in the body, but no conclusive results have been found. The chemical structure and purity of N-Desmethyl trimeprazine are not listed in the USP or BP. This compound can be custom synthesized on request.

Please enquire for more information about (E/Z)-It-603 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Xanthoxin is a medicinal compound with potent anticancer properties. It has been shown to induce apoptosis, or programmed cell death, in cancer cells. Xanthoxin has been tested in various cancer cell lines, including Chinese and human cells, and has demonstrated strong inhibitory effects on the tumor cycle. This compound works by inhibiting kinases and other proteins involved in cancer cell growth and proliferation. Xanthoxin is also known to be an inhibitor of certain urinary proteins that are associated with cancer progression. Overall, Xanthoxin shows great potential as a natural product for the development of novel anticancer therapies.

1-Phenyl-1,2,3,4-tetrahydro-isoquinoline is a synthetic compound which has been used as a lead compound for the development of drugs with dopamine β-hydroxylase inhibitory activity. In vitro studies have shown that 1-phenyl-1,2,3,4-tetrahydro-isoquinoline inhibits human serum dopamine β-hydroxylase and can be used to study the possible role of this enzyme in Parkinson's disease. This drug is racemized in the body and has been found to be effective against Parkinson's disease in rats. It is also an enantiomer that has industrial applications for the production of polyurethane foam insulation coatings.

CPI 0610 is a medicinal compound that acts as a potent inhibitor of protein phosphorylation. It has been shown to inhibit the cell cycle and promote apoptosis in Chinese hamster ovary cells. CPI 0610 is an effective inhibitor of kinase activity in cancer cells, leading to decreased tumor growth and increased survival rates. In preclinical studies, CPI 0610 has demonstrated efficacy against a wide range of cancers, including breast, prostate, and lung cancer. This inhibitor has also been shown to be effective in human cancer cell lines, making it a promising candidate for future cancer therapies.

4-(Phthalazin-1-yloxy)aniline is an analog of cyclin-dependent kinase (CDK) inhibitors that has shown promising anticancer activity. It inhibits the activity of CDKs, which are enzymes involved in regulating cell division and proliferation. This compound has been tested on Chinese hamster ovary cells and has demonstrated potent antiproliferative activity against various cancer cell lines. 4-(Phthalazin-1-yloxy)aniline induces apoptosis in tumor cells, leading to their death. This compound may be a potential candidate for the development of novel anticancer drugs that target CDKs and promote tumor cell death. Additionally, this compound can be detected in urine samples, making it a useful biomarker for cancer diagnosis and monitoring.

Simvastatin acid is the active form of simvastatin, a drug used to lower blood cholesterol levels. Simvastatin acid inhibits HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate. This conversion is a rate-limiting step in the synthesis of cholesterol and other lipids. Simvastatin acid binds to polymerase chain and drug transporter proteins, which leads to cell lysis. The concentration–time curve for simvastatin acid is linear and the half-life is approximately 12 hours. When simvastatin acid is administered with drugs that are potent inducers of CYP3A4 or UGT1A1 enzymes, there may be an increased risk for drug interactions. Simvastatin acid has shown no significant human pharmacokinetic interactions with food or grapefruit juice at doses up to 200 mg/day. There are limited data on the pharmacokinetics of simvastatin